BOCFBaseline Observation Carried Forward
BOCFBears of Central Florida
References in periodicals archive ?
Although the BOCF analysis yielded statistically significant results, the FDA may not accept this as a registration study.
067 for LOCF and BOCF analyses respectively), indicating a durable response to milnacipran treatment.
Actual results could vary materially from those described as a result of a number of factors, including those set forth in Cypress Annual Report on Form 10-K, the most recent Quarterly Report on Form 10-Q and any subsequent SEC filings and including, but not limited to, the fact that because we did not achieve statistical significance on our primary endpoints, that the FDA may not accept this trial as one of the two pivotal trials required for NDA approval, that the FDA may not allow us to use the BOCF analysis and that upon further analysis of this trial, that we and Forest may elect not to continue development of milnacipran.